Advertisement

Impact of CVOTs in primary and secondary prevention of kidney disease

  • Author Footnotes
    1 Department of Clinical Science, IRCCS Casa Sollievo della sofferenza, Viale dei Cappuccini, 71013 San Giovanni Rotondo, FG, Italy.
    Salvatore De Cosmo
    Footnotes
    1 Department of Clinical Science, IRCCS Casa Sollievo della sofferenza, Viale dei Cappuccini, 71013 San Giovanni Rotondo, FG, Italy.
    Affiliations
    Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG 71013, Italy
    Search for articles by this author
  • Francesca Viazzi
    Affiliations
    Università degli Studi and IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Pamela Piscitelli
    Affiliations
    Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG 71013, Italy
    Search for articles by this author
  • Giovanna Leoncini
    Affiliations
    Università degli Studi and IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Antonio Mirijello
    Affiliations
    Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG 71013, Italy
    Search for articles by this author
  • Barbara Bonino
    Affiliations
    Università degli Studi and IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Author Footnotes
    2 Department of Internal Medicine, Università degli Studi and IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6, 16132 Genova, Italy.
    Roberto Pontremoli
    Correspondence
    Corresponding author at: Università degli Studi e IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6 -16132 Genoa, Italy.
    Footnotes
    2 Department of Internal Medicine, Università degli Studi and IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6, 16132 Genova, Italy.
    Affiliations
    Università degli Studi and IRCCS Ospedale Policlinico San Martino, Genoa, Italy
    Search for articles by this author
  • Author Footnotes
    1 Department of Clinical Science, IRCCS Casa Sollievo della sofferenza, Viale dei Cappuccini, 71013 San Giovanni Rotondo, FG, Italy.
    2 Department of Internal Medicine, Università degli Studi and IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6, 16132 Genova, Italy.
Published:October 29, 2019DOI:https://doi.org/10.1016/j.diabres.2019.107907

      Abstract

      Type 2 diabetes mellitus is the leading cause of end stage renal disease worldwide. Diabetic kidney disease, whose main clinical manifestations are albuminuria and decline of glomerular filtration rate, affects up to 40% of patients. Sodium Glucose cotransporter-2 inhibitors (SGLT2-is) and Glucagon-like peptide-1 receptor agonists (GLP-1ras) are new classes of anti-hyperglycemic drugs which have demonstrated to improve renal outcome.
      Renal benefits of both SGLT2-is and GLP-1ras are acknowledged from data of large randomized phase III clinical trials conducted to assess their cardiovascular safety.
      In this review, we will focus on renal results of major cardiovascular outcome trials, and we will describe direct and indirect mechanisms through which they confer renal protection.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Viazzi F.
        • Russo G.T.
        • Ceriello A.
        • Fioretto P.
        • Giorda C.
        • De Cosmo S.
        • et al.
        Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.
        J Nephrol. 2018; : 561-563
        • Chamberlain J.J.
        • Herman W.H.
        • Leal S.
        • Rhinehart A.S.
        • Shubrook J.H.
        • Skolnik N.
        • Kalyani R.R.
        Pharmacologic therapy for Type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
        Ann Intern Med. 2017; 2017: 572-657
        • Hirshberg B.
        • Raz I.
        Impact of tge U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.
        Diab Care. 2011; 34: S101-S106
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • Fitchett D.
        • Bluhmki E.
        • Hantel S.
        • EMPA-REG OUTCOME Investigators
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Wanner C.
        • Inzucchi S.E.
        • Lachin J.M.
        • Fitchett D.
        • von Eynatten M.
        • Mattheus M.
        • EMPA-REG OUTCOME Investigators
        • et al.
        Empagliflozin and progression of kidney disease in Type 2 diabetes.
        N Engl J Med. 2016; 375: 323-334
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • de Zeeuw D.
        • Fulcher G.
        • Erondu CANVAS Program Collaborative Group N.
        • et al.
        Canagliflozin and cardiovascular and renal events in Type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Perkovic V.
        • de Zeeuw D.
        • Mahaffey K.W.
        • Fulcher G.
        • Erondu N.
        • Shaw W.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
        Lancet Diab Endocrinol. 2018; 6: 691-704
        • Zelniker T.A.
        • Wiviott S.D.
        • Raz I.
        • Im K.
        • Goodrich E.L.
        • Bonaca M.P.
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • Bompoint S.
        • Heerspink H.J.L.
        • Charytan D.M.
        • CREDENCE Trial Investigators
        • et al.
        Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy.
        N Engl J Med. 2019; : 2295-2306
        • Heerspink H.J.L.
        • Kosiborod M.
        • Inzucchi S.E.
        • Cherney D.Z.I.
        Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
        Kidney Int. 2018; 94: 26-39
      1. Circulation. 2014; 129: 587-597https://doi.org/10.1161/CIRCULATIONAHA.113.005081
        • Davies M.J.
        • D'Alessio D.A.
        • Fradkin J.
        • Kernan W.N.
        • Mathieu C.
        • Mingrone G.
        • et al.
        A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diab Care. 2018; 2018: 2669-2701
        • Baggio L.L.
        • Drucker D.J.
        Biology of incretins: GLP-1 and GIP.
        Gastroenterology. 2007; 132: 2131-2157
        • Marso S.P.
        • Daniels G.H.
        • Brown-Frandsen K.
        • Kristensen P.
        • Mann J.F.
        • Nauck M.A.
        • LEADER Steering Committee and LEADER Trial Investigators
        • et al.
        Liraglutide and cardiovascular outcomes in Type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322https://doi.org/10.1056/NEJMoa1603827
        • Mann J.F.E.
        • Ørsted D.D.
        • Brown-Frandsen K.
        • Marso S.P.
        • Poulter N.R.
        • Rasmussen S.
        • LEADER Steering Committee and Investigators
        • et al.
        Liraglutide and renal outcomes in Type 2 diabetes.
        N Engl J Med. 2017; 377: 839-848https://doi.org/10.1056/NEJMoa1616011
        • Marso S.P.
        • Bain S.C.
        • Consoli A.
        • Eliaschewitz F.G.
        • Jódar E.
        • Leiter L.A.
        • SUSTAIN-6 Investigators
        • et al.
        Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes.
        N Engl J Med. 2016; 375: 1834-1844
        • Pfeffer M.A.
        • Claggett B.
        • Diaz R.
        • Dickstein K.
        • Gerstein H.C.
        • Køber L.V.
        • ELIXA Investigators
        • et al.
        Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome.
        N Engl J Med. 2015; 373: 2247-2257https://doi.org/10.1056/NEJMoa1509225
        • Muskiet M.H.A.
        • Tonneijck L.
        • Huang Y.
        • Liu M.
        • Saremi A.
        • Heerspink H.J.L.
        • et al.
        Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
        Lancet Diab Endocrinol. 2018; 6: 859-869https://doi.org/10.1016/S2213-8587(18)30268-7
      2. N Engl J Med. 2017; 377: 1228-1239https://doi.org/10.1056/NEJMoa1612917
        • Bethel M.A.
        • Mentz R.J.
        • Merrill P.
        • Buse J.B.
        • Chan J.C.
        • Shaun G.
        • et al.
        Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
        Diabetes. 2018; 67https://doi.org/10.2337/db18-522-P
        • Tuttle K.R.
        • Lakshmanan M.C.
        • Rayner B.
        • Busch R.S.
        • Zimmermann A.G.
        • Woodward D.B.
        • et al.
        Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
        Lancet Diab Endocrinol. 2018; 6: 605-617https://doi.org/10.1016/S2213-8587(18)30104-9
        • Gerstein H.C.
        • Colhoun H.M.
        • Dagenais G.R.
        • Diaz R.
        • Lakshmanan M.
        • Pais P.
        • et al.
        Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
        Lancet. 2019; 394: 131-138
        • Zelniker T.A.
        • Wiviott S.D.
        • Raz I.
        • Im K.
        • Goodrich E.L.
        • Furtado R.H.M.
        • et al.
        Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in Type 2 diabetes mellitus.
        Circulation. 2019; 139: 2022-2031
        • Kristensen S.L.
        • Rørth R.
        • Jhund P.S.
        • Docherty K.F.
        • Sattar N.
        • Preiss D.
        • et al.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet Diab Endocrinol. 2019; (pii: S2213-8587(19)30249-9): 30249-30259https://doi.org/10.1016/S2213-8587(19)30249
        • Heerspink H.J.L.
        • Greene T.
        • Tighiouart H.
        • Gansevoort R.T.
        • Coresh J.
        • Simon A.L.
        • et al.
        Chronic Kidney Disease Epidemiology Collaboration Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
        Lancet Diab Endocrinol. 2019; 7: 128-139
        • Muskiet M.H.A.
        • Tonneijck L.
        • Smits M.M.
        • van Baar M.J.B.
        • Kramer M.H.H.
        • Hoorn E.J.
        • et al.
        GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
        Nat Rev Nephrol. 2017; 13: 605-628
        • Dieter B.P.
        • Alicic R.Z.
        • Tuttle K.R.
        GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.
        Am J Physiol Renal Physiol. 2018; 315: F1519-F1525
        • Ruospo M.
        • Saglimbene V.M.
        • Palmer S.C.
        • De Cosmo S.
        • Pacilli A.
        • Lamacchia O.
        • et al.
        Glucose targets for preventing diabetic kidney disease and its progression.
        Cochrane Datab Syst Rev. 2017; 6: CD010137
        • Patel A.
        • MacMahon S.
        • Chalmers J.
        • Neal B.
        • Woodward M.
        • Billot L.
        • et al.
        Effects of a fixed combination perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
        Lancet. 2007; 370: 829-840
        • Crajoinas R.O.
        • Oricchio F.T.
        • Pessoa T.D.
        • Pacheco B.P.
        • Lessa L.M.
        • Malnic G.
        • et al.
        Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
        Am J Physiol Renal Physiol. 2011; 301: F355-F363https://doi.org/10.1152/ajprenal.00729.2010
        • Gutzwiller J.P.
        • Tschopp S.
        • Bock A.
        • Drewe J.
        • Beglinger C.
        • Sieber C.C.
        Glucagon-like peptide-1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
        J Clin Endocrinol Metab. 2004; 89: 3055-3061
        • Câmara N.O.
        • Iseki K.
        • Kramer H.
        • Liu Z.H.
        • Sharma K.
        Kidney disease and obesity: epidemiology, mechanisms and treatment.
        Nat Rev Nephrol. 2017; 13: 181-190https://doi.org/10.1038/nrneph.2016.191
        • Pyke C.
        • Heller R.S.
        • Kirk R.K.
        • Ørskov C.
        • Reedtz-Runge S.
        • Kaastrup P.
        • et al.
        GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
        Endocrinology. 2014; 155: 1280-1290https://doi.org/10.1210/en.2013-1934
        • Körner M.
        • Stöckli M.
        • Waser B.
        • Reubi J.C.
        GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
        J Nucl Med. 2007; 48: 736-743
        • Fujita H.
        • Morii T.
        • Fujishima H.
        • Sato T.
        • Shimizu T.
        • Hosoba M.
        • et al.
        The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
        Kidney Int. 2014; 85: 579-589https://doi.org/10.1038/ki.2013.427
        • Kodera R.
        • Shikata K.
        • Kataoka H.U.
        • Takatsuka T.
        • Miyamoto S.
        • Sasaki M.
        • et al.
        Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
        Diabetologia. 2011; 54: 965-978https://doi.org/10.1007/s00125-010-2028-x
        • Wang C.
        • Li L.
        • Liu S.
        • Liao G.
        • Li L.
        • Chen Y.
        • et al.
        GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis.
        PLoS ONE. 2018; 13: e0193473
        • Elmarakby A.A.
        • Sullivan J.C.
        Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
        Cardiovasc Ther. 2012; 30: 49-59https://doi.org/10.1111/j.1755-5922.2010.00218.x
        • Hendarto H.
        • Inoguchi T.
        • Maeda Y.
        • Ikeda N.
        • Zheng J.
        • Takei R.
        • et al.
        GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
        Metabolism. 2012; 61: 1422-1434https://doi.org/10.1016/j.metabol.2012.03.002
        • Sourris K.C.
        • Yao H.
        • Jerums G.
        • Cooper M.E.
        • Ekinci E.I.
        • Coughlan M.T.
        Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy?.
        Curr Drug Targets. 2016; 17: 1252-1264
        • Skov J.
        • Pedersen M.
        • Holst J.J.
        • Madsen B.
        • Goetze J.P.
        • Rittig S.
        • et al.
        Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
        Diab Obes Metab. 2016; 18: 581-589https://doi.org/10.1111/dom.12651
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • Kober L.
        • Kosiborod M.N.
        • Martinez F.A.
        • DAPA-HF Tril Committees and investigators
        • et al.
        Dapaglifozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; https://doi.org/10.1056/NEJMoa1911303